Samsung Medical Center
CAR T-cell therapy in the Republic of Korea typically costs from $385,000 to $515,000. The total price depends on the specific drug used, hospital stay duration, and side-effect monitoring. In the United States, patients pay $525,000 on average for this treatment. South Korea offers savings of approximately 27%. Costs generally cover cell collection, genetic engineering, and the infusion process.
Bookimed Expert Insight: Choosing a high-volume center like Samsung Medical Center provides access to presidential-standard care. This facility serves over 2,000,000 patients annually and holds KOIHA accreditation. The hospital integrates Da Vinci systems and Novalis technology within its Comprehensive Cancer Center. International patients benefit from standardized protocols that match US quality at a significantly lower price point. For those without local insurance, Seoul remains the most cost-effective hub for Kymriah therapy.
Why consider the Republic of Korea for CAR T-cell therapy?
Access advanced CAR T-cell therapy solutions in trusted clinics .
| Republic of Korea | Turkey | Austria | |
| CAR T-cell therapy | from $385,000 | from $150,000 | from $350,000 |
No hidden fees – just official clinic prices. Pay at the clinic for CAR T-cell therapy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in CAR T-cell therapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your CAR T-cell therapy journey.
Day 1
Day 2 - Day 3
Day 4
Day 5 - Day 12
Day 13
Day 14 - Day 20
Week 3 - Week 4
Week 5 onwards
Please note that each case is individual. This timeline may vary based on your personal health condition and the specifics of your treatment plan.
The doctor heads the Division of Hematology-Oncology and graduated from Seoul National University College of Medicine.
Specializes in lung cancer, head and neck cancer, and esophageal cancer. Holds memberships in several prestigious organizations, including the Korean Medical Association, American Society of Clinical Oncology, and the European Society of Medical Oncology.
Written by Anna Leonova
Qualified centers in South Korea must receive Ministry of Food and Drug Safety approval to administer CAR T-cell therapy. Primary authorized facilities include Samsung Medical Center, Seoul National University Hospital, and Seoul St. Mary Hospital. These institutions manage commercial products like Kymriah for lymphoma and leukemia patients.
Bookimed Expert Insight: Samsung Medical Center serves over 2,000,000 patients annually and maintains a presidential-tier infrastructure. This high volume translates to significant experience in complex oncology. Their early adoption of a dedicated center makes them a leader in managing cytokine release syndrome. This specialized care is vital for patient safety during the aggressive CAR T-cell infusion phase.
Patient Consensus: Patients emphasize the need for official verification. They recommend contacting oncology departments directly to confirm current KFDA approval status for specific therapies. Many suggest budgeting over $300,000 and planning for a 6-week stay.
South Korea's Ministry of Food and Drug Safety has approved four major CAR T-cell therapies: Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Carvykti (ciltacabtagene autoleucel), and Rimqarto (anbalcabtagene autoleucel). These products treat specific lymphomas and multiple myeloma. Administration occurs at specialized centers like Samsung Medical Center.
Bookimed Expert Insight: While approvals are increasing, manufacturing logistics remain a significant bottleneck. Data shows patients often wait over 6 months for imported products. Top centers like Samsung Medical Center manage these timelines better due to high patient volumes. They serve over 2,000,000 patients annually and have established apheresis protocols.
Patient Consensus: Patients emphasize the need to verify hospital capabilities early. They often report that insurance coverage lags behind regulatory approval, making out-of-pocket costs a major concern.
South Korea National Health Insurance covers CAR T-cell therapy primarily for relapsed or refractory diffuse large B-cell lymphoma and pediatric B-cell acute lymphoblastic leukemia. Coverage usually applies starting from third-line treatment under strict National Health Insurance Service guidelines at accredited medical centers.
Bookimed Expert Insight: Samsung Medical Center serves over 2,000,000 patients annually and holds KOIHA accreditation for safety. Their high volume suggests they manage the complex National Health Insurance reimbursement and hospital-level approvals efficiently. Patients should verify their specific malignancy against the latest risk-sharing agreements at such high-capacity centers.
Patient Consensus: Patients report that while pediatric leukemia coverage is reliable, many adults with multiple myeloma face private costs. Most advise preparing for a 10% to 20% copay even when insurance approves the treatment.
South Korea actively recruits for CAR T-cell clinical trials targeting lymphoma, leukemia, and liver cancer. Prominent studies include the ALPHA3 trial for B-cell lymphoma and the EU307 phase 1 trial for hepatocellular carcinoma. Enrollment centers include Samsung Medical Center and Seoul National University Hospital.
Bookimed Expert Insight: While many global trials use ClinicalTrials.gov, South Korean centers often prioritize the local CRIS registry. Samsung Medical Center, which serves over 2,000,000 patients annually, frequently operates internal trial pipelines. Checking their specific Cancer Center listings usually reveals more active slots than international databases.
Patient Consensus: Many find that trial information is mainly available in Korean. Direct contact with tier-1 hospital international departments is more effective than searching public online listings.